Voyager Therapeutics
VYGR
75 hedge funds and large institutions have $233M invested in Voyager Therapeutics in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 7 closing their positions.
17,071% more call options, than puts
Call options by funds: $3.61M | Put options by funds: $21K
329% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 7
137% more capital invested
Capital invested by funds: $98.1M → $233M (+$135M)
117% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 12
44% more funds holding
Funds holding: 52 → 75 (+23)
1.28% more ownership
Funds ownership: 40.78% → 42.06% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$3.23M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.05M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.95M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.83M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$10.5M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.14M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.35M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$988K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$722K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCPEM
76
Bain Capital Public Equity Management
Boston,
Massachusetts
| – | -$10.5M | -1,176,470 | Closed |
|
|
77
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$1.35M | -150,384 | Closed |
|
78
Bessemer Group
Woodbridge,
New Jersey
| – | -$402K | -44,828 | Closed |
|
|
HP
79
Harbourvest Partners
Boston,
Massachusetts
| – | -$400K | -44,606 | Closed |
|
|
HTC
80
Hershey Trust Company
Hershey,
Pennsylvania
| – | -$129K | -14,394 | Closed |
|
|
GEA
81
Glen Eagle Advisors
Kingston,
New Jersey
| – | -$4.48K | -500 | Closed |
|
82
Citigroup
New York
| – | -$1K | -97 | Closed |
|
VYGR Hedge Fund Activity: Q3 2017 in Review
75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2017, worth a combined $233M — up 137% from $98.1M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new VYGR positions and 7 closed out — a net gain of 23 holders — while 26 added to existing stakes and 12 trimmed.
The largest buyer was Wells Fargo, adding an estimated $3.23M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $10.5M sold.
- 75 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2017, up from 52 in Q2 2017.
- Funds reported $233M of Voyager Therapeutics stock for Q3 2017, up 137% quarter-over-quarter.
- 30 funds opened new Voyager Therapeutics positions in Q3 2017 and 7 closed out, a net change of +23 holders.
- The largest Voyager Therapeutics buyer in Q3 2017 was Wells Fargo, an estimated $3.23M added.
- The largest Voyager Therapeutics seller in Q3 2017 was Bain Capital Public Equity Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q3 2017.